Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Anaprazole in the Treatment of Reflux Esophagitis: A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Positive-Controlled Phase III Clinical Trial.

NCT07010107 is registered in ClinicalTrials.gov with Xuanzhu Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07010107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07010107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Anaprazole in the Treatment of Reflux Esophagitis: A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Positive-Controlled Phase III Clinical Trial.
Lead sponsor
Xuanzhu Biopharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
July 30, 2025
Completion date
August 31, 2026
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

reflux esophagitis (re)